- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple myeloma with acute light chain cast nephropathy
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-03-29
DOI
10.1038/s41408-023-00806-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
- (2022) Alissa Visram et al. LEUKEMIA
- Monoclonal Gammopathy of Renal Significance
- (2021) Nelson Leung et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
- (2021) Efstathios Kastritis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study
- (2020) Punit Yadav et al. Blood Cancer Journal
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study
- (2020) Virginie Royal et al. BLOOD
- Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy
- (2020) Frank Bridoux et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal impairment at diagnosis in myeloma: patient characteristics, treatment and impact on outcomes. Results from the Australia and New Zealand Myeloma & Related Diseases Registry
- (2019) P Joy Ho et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial
- (2019) Colin A Hutchison et al. Lancet Haematology
- Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury
- (2019) Wei-Zhong Ying et al. JOURNAL OF CLINICAL INVESTIGATION
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry
- (2019) Maxime Courant et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
- (2018) Meletios Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
- (2018) Punit Yadav et al. BMC Nephrology
- Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study
- (2018) Joseph Mikhael et al. Blood Cancer Journal
- Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy
- (2017) Frank Bridoux et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proteasome inhibitor associated thrombotic microangiopathy
- (2016) Jennifer C. Yui et al. AMERICAN JOURNAL OF HEMATOLOGY
- A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
- (2016) Neeraj Gupta et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment
- (2016) Frank Bridoux et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma
- (2015) W I Gonsalves et al. Blood Cancer Journal
- Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study
- (2014) H. Ludwig et al. HAEMATOLOGICA
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
- (2013) Francesca Gay et al. Expert Opinion on Drug Metabolism & Toxicology
- Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial
- (2013) C. Scheid et al. HAEMATOLOGICA
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
- (2013) A Z Badros et al. LEUKEMIA
- Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment
- (2012) Meletios A. Dimopoulos et al. CANCER TREATMENT REVIEWS
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases
- (2012) N. Leung et al. Clinical Journal of the American Society of Nephrology
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of Light Chain Injury along the Tubular Nephron
- (2012) P. W. Sanders JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney
- (2011) C. A. Hutchison et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange
- (2011) Brian L. Burnette et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunoglobulin light chains activate nuclear factor- B in renal epithelial cells through a Src-dependent mechanism
- (2010) W.-Z. Ying et al. BLOOD
- Renal function in newly diagnosed multiple myeloma - A demographic study of 1353 patients
- (2010) Lene Meldgaard Knudsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study
- (2010) Heinz Ludwig et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
- (2010) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis
- (2009) C. A. Hutchison et al. Clinical Journal of the American Society of Nephrology
- Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
- (2009) Martina Kleber et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- VMP (Bortezomib, Melphalan, and Prednisone) Is Active and Well Tolerated in Newly Diagnosed Patients With Multiple Myeloma With Moderately Impaired Renal Function, and Results in Reversal of Renal Impairment: Cohort Analysis of the Phase III VISTA Study
- (2009) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
- (2008) N. Leung et al. KIDNEY INTERNATIONAL
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started